X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GHB1589M is an inhaled oligonucleotide therapeutic for idiopathic pulmonary fibrosis, or IPF. Oligonucleotide therapies are a promising therapeutic approach for the treatment of IPF as they can inhibit pathways that are otherwise difficult to target.
Lead Product(s): GHB1589M
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GHB1589M
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
The collaboration is expected to accelerate the development of a broad range of novel therapeutics iincluding GHB-002, leveraging the unexplored small non-coding area of the genome.
Lead Product(s): GHB-002
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GHB-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
